Table 4 Uni-factorial analysis and distribution of clinico-pathological factors
From: Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran
Unifactorial analysis | Distribution of factors | |||
|---|---|---|---|---|
| Â | Hazard ratio (95%CI) | p | numbers | % |
Tumour side | Â | Â | 1064 | 93 |
   Right | 1 | 0.562 | 565 | 49 |
   Left | 1.08 (0.84–1.39) |  | 499 | 4 |
Tumour location | Â | Â | 440 | 38 |
   Lateral | 1 | 0.258 | 322 | 28 |
   Medial | 0.75 (0.42–1.36) |  | 68 | 6 |
   Central | 0.60 (0.30–1.97) |  | 50 | 4 |
Tumour size | Â | Â | 1055 | 92 |
   ≤ 2 cm | 1 | 0.000 | 298 | 26 |
   >2 & <5 cm | 1.82 (1.30–2.70) |  | 523 | 46 |
   ≥ 5 cm | 3.04 (2.05–4.50) |  | 234 | 20 |
Tumour grade | Â | Â | 1059 | 92 |
   Well-differentiated | 1 | 0.000 | 250 | 22 |
   Moderately-differentiated | 1.89 (1.28–2.78) |  | 637 | 55 |
   Poorly-differentiated | 4.53 (2.99–6.86) |  | 172 | 15 |
Nuclear grade | Â | Â | 140 | 12 |
   Low | 1 | 0.068 | 33 | 3 |
   Intermediate | 10.88 (1.00–80.75) |  | 91 | 8 |
   High | 5.70 (0.59–54.90) |  | 16 | 1 |
Co-morbidity | Â | Â | 352 | 31 |
   GI&Respiratory | 1 | 0.433 | 37 | 3 |
   Cardiovascular | 0.92 (0.44–1.95) |  | 122 | 11 |
   Psycho.&Neurological | 0.69 (0.28–1.57) |  | 55 | 5 |
   Gynaecologic | 1.42 (0.61–3.29) |  | 39 | 3 |
   Endocrine&Metabolic | 1.13 (0.55–2.33) |  | 99 | 9 |
No. of stillbirths | Â | Â | 1097 | 96 |
   0 | 1 | 0.581 | 997 | 87 |
   1–3 | 1.19 (0.78–1.83) |  | 92 | 8 |
   >3 | 1.48 (0.47–4.62) |  | 8 | 1 |
No. of abortions | Â | Â | 1106 | 96 |
   0 | 1 | 0.525 | 819 | 71 |
   1–3 | 0.85 (0.64–1.14) |  | 269 | 23 |
   >3 | 0.80 (0.30–2.15) |  | 18 | 2 |
Histological type | Â | Â | 1062 | 93 |
   IDC | 1 | 0.086 | 942 | 82 |
   ILC | 0.68 (0.31–1.55) |  | 33 | 3 |
   Med.C | 0.35 (0.14–0.84) |  | 60 | 5 |
   MLDC | 1.55 (0-.) |  | 3 | <1 |
   Muc.C | 0.65 (0.09–4.62) |  | 6 | <1 |
   IPC | 1.33 (0.42–4.15) |  | 10 | 1 |
   Met.C | 3.31 (1.05–10.39) |  | 8 | 1 |
No. of excised lymph nodes | Â | Â | 1048 | 91 |
   0 | 1 | 0.007 | 20 | 2 |
   1–10 | 1.48 (0.46–4.74) |  | 263 | 23 |
   11–20 | 1.93 (0.61–6.09) |  | 553 | 48 |
   21–30 | 2.29 (0.713–7.37) |  | 189 | 16 |
   >30 | 4.67 (1.28–17.03) |  | 23 | 2 |
Lymph node ratio | Â | Â | 1027 | 89 |
   0 | 1 | 0.000 | 331 | 29 |
   >0 & ≤ .3 | 1.98 (1.06–3.66) |  | 246 | 21 |
   >.3 & ≤ .6 | 5.24 (2.96–9.29) |  | 156 | 14 |
   >.6 & < 1 | 11.26 (6.68–18.96) |  | 185 | 16 |
   1 | 18.87 (11.09–32.08) |  | 109 | 9 |
No. of involved lymph nodes | Â | Â | 1046 | 91 |
   0 | 1 | 0.000 | 349 | 30 |
   1–5 | 3.03 (1.82–5.04) |  | 346 | 30 |
   6–10 | 6.59 (3.89–11.15) |  | 146 | 13 |
   11–15 | 10.16 (6.13–16.84) |  | 123 | 11 |
   >15 | 18.78 (11.21–31.45) |  | 82 | 7 |
Tumour calcification | Â | Â | 1022 | 89 |
   No | 1 | 0.000 | 740 | 64 |
   Yes | 1.67 (1.28–2.19) |  | 282 | 25 |
Tumour necrosis | Â | Â | 317 | 28 |
   No | 1 | 0.017 | 157 | 14 |
   Yes | 1.82 (1.11–2.97) |  | 160 | 14 |
Nipple involvement | Â | Â | 995 | 87 |
   No | 1 | 0.000 | 887 | 77 |
   Yes | 1.84 (1.32–2.57) |  | 108 | 10 |
Skin involvement | Â | Â | 1013 | 88 |
   No | 1 | 0.000 | 946 | 82 |
   Yes | 2.06 (1.39–3.05) |  | 67 | 6 |
Vascular invasion | Â | Â | 1035 | 90 |
   No | 1 | 0.000 | 604 | 53 |
   Yes | 1.90 (1.47–2.46) |  | 431 | 37 |
Lymphatic invasion | Â | Â | 1006 | 88 |
   No | 1 | 0.000 | 419 | 36 |
   Yes | 3.73 (2.67–5.20) |  | 587 | 52 |
Treatment | Â | Â | 1134 | 99 |
   S&C&R | 1 | 0.000 | 927 | 81 |
   C&S&R | 1.86 (1.39–2.50) |  | 178 | 16 |
   S&R | 1.27 (0.56–2.87) |  | 29 | 2 |
Type of surgery | Â | Â | 1065 | 93 |
   MRM | 1 | 0.000 | 649 | 57 |
   RM | 1.09 (0.64–1.86) |  | 62 | 5 |
   TM | 1.60 (1.13–2.28) |  | 99 | 9 |
   L | 0.58 (0.37–0.90) |  | 164 | 14 |
   Q | 0.32 (0.14–0.73) |  | 85 | 7 |
   PM | 2.66 (0.85–8.36) |  | 6 | 1 |